nach oben

Inflammation Research

Erschienen in:

21.09.2021 | Review

Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer

verfasst von: Hang Yang, Bin Wei, Bing Hu

Erschienen in: Inflammation Research | Ausgabe 10-12/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Helicobacter pylori (H. pylori) infects approximately half of the world’s population, as one of the most common chronic infections. H. pylori infection has been widely recognized as a major risk factor for gastric cancer (GC).

Methods

Eradication treatment is considered to abolish the inflammatory response and prevent progression to GC. However, only 1–3% of H. pylori-infected patients develop GC, whereas GC can occur even after eradicating H. pylori. In addition, the incidence of GC following H. pylori infection is significantly higher compared to the gross incidence induced by all causes, although eradicating H. pylori reduces the risk of developing GC.

Results

Therefore, it is reasonable to hypothesize that H. pylori infection results in changes that persist even after its eradication. Several of these changes may not be reversible within a short time, including the status of inflammation, the dysfunction of immunity and apoptosis, mitochondrial changes, aging and gastric dysbacteriosis.

Conclusion

The present review article aimed to discuss these potential long-lasting changes induced by H. pylori infection that may follow the eradication of H. pylori and contribute to the development of GC.

Kato S, Shimizu T, Toyoda S, Gold BD, Ida S, Ishige T, et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int. 2020;62(12):1315–31. https://doi.org/10.1111/ped.14388.CrossRefPubMedPubMedCentral

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9. https://doi.org/10.1053/j.gastro.2017.04.022.CrossRefPubMed

Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093–112. https://doi.org/10.1136/gutjnl-2020-322368.CrossRefPubMed

Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.CrossRefPubMed

Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243–50. https://doi.org/10.1136/gutjnl-2020-322200.CrossRefPubMed

Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382(5):427–36. https://doi.org/10.1056/NEJMoa1909666.CrossRefPubMed

Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication—a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–90. https://doi.org/10.1111/apt.14424.CrossRefPubMed

Tahara T, Shibata T, Horiguchi N, Kawamura T, Okubo M, Ishizuka T, et al. A possible link between gastric mucosal atrophy and gastric cancer after Helicobacter pylori eradication. PLoS ONE. 2016;11(10): e0163700. https://doi.org/10.1371/journal.pone.0163700.CrossRefPubMedPubMedCentral

Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020;55(3):281–8. https://doi.org/10.1007/s00535-019-01639-w.CrossRefPubMed

10.

Maehata Y, Nakamura S, Esaki M, Ikeda F, Moriyama T, Hida R, et al. Characteristics of primary and metachronous gastric cancers discovered after Helicobacter pylori eradication: a multicenter propensity score-matched study. Gut Liver. 2017;11(5):628–34. https://doi.org/10.5009/gnl16357.CrossRefPubMedPubMedCentral

11.

Schreiber S, Konradt M, Groll C, Scheid P, Hanauer G, Werling HO, et al. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci USA. 2004;101(14):5024–9. https://doi.org/10.1073/pnas.0308386101.CrossRefPubMedPubMedCentral

12.

Bugaytsova JA, Björnham O, Chernov YA, Gideonsson P, Henriksson S, Mendez M, et al. Helicobacter pylori adapts to chronic infection and gastric disease via pH-responsive BabA-mediated adherence. Cell Host Microbe. 2017;21(3):376–89. https://doi.org/10.1016/j.chom.2017.02.013.CrossRefPubMedPubMedCentral

13.

Fischer W. Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J. 2011;278(8):1203–12. https://doi.org/10.1111/j.1742-4658.2011.08036.x.CrossRefPubMed

14.

Lin AS, Dooyema SDR, Frick-Cheng AE, Harvey ML, Suarez G, Loh JT, et al. Bacterial energetic requirements for Helicobacter pylori Cag type IV secretion system-dependent alterations in gastric epithelial cells. Infect Immun. 2020. https://doi.org/10.1128/iai.00790-19.CrossRefPubMedPubMedCentral

15.

Arnold IC, Zhang X, Urban S, Artola-Borán M, Manz MG, Ottemann KM, et al. NLRP3 controls the development of gastrointestinal CD11b(+) dendritic cells in the steady state and during chronic bacterial infection. Cell Rep. 2017;21(13):3860–72. https://doi.org/10.1016/j.celrep.2017.12.015.CrossRefPubMed

16.

Varga MG, Shaffer CL, Sierra JC, Suarez G, Piazuelo MB, Whitaker ME, et al. Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system. Oncogene. 2016;35(48):6262–9. https://doi.org/10.1038/onc.2016.158.CrossRefPubMedPubMedCentral

17.

Xie C, Yi J, Lu J, Nie M, Huang M, Rong J, et al. N-acetylcysteine reduces ROS-mediated oxidative DNA damage and PI3K/Akt pathway activation induced by Helicobacter pylori infection. Oxid Med Cell Longev. 2018;2018:1874985. https://doi.org/10.1155/2018/1874985.CrossRefPubMedPubMedCentral

18.

Handa O, Naito Y, Yoshikawa T. Helicobacter pylori: a ROS-inducing bacterial species in the stomach. Inflamm Res. 2010;59(12):997–1003. https://doi.org/10.1007/s00011-010-0245-x.CrossRefPubMed

19.

Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science. 2002;295(5555):683–6. https://doi.org/10.1126/science.1067147.CrossRefPubMed

20.

Wang YC, Chen CL, Sheu BS, Yang YJ, Tseng PC, Hsieh CY, et al. Helicobacter pylori infection activates Src homology-2 domain-containing phosphatase 2 to suppress IFN-γ signaling. J Immunol. 2014;193(8):4149–58. https://doi.org/10.4049/jimmunol.1400594.CrossRefPubMed

21.

Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306–16. https://doi.org/10.1016/j.chom.2014.02.008.CrossRefPubMed

22.

Nagase L, Murata-Kamiya N, Hatakeyama M. Potentiation of Helicobacter pylori CagA protein virulence through homodimerization. J Biol Chem. 2011;286(38):33622–31. https://doi.org/10.1074/jbc.M111.258673.CrossRefPubMedPubMedCentral

23.

Park CH, Lee AR, Lee YR, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24(1): e12547. https://doi.org/10.1111/hel.12547.CrossRefPubMed

24.

Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA. 2008;105(3):1003–8. https://doi.org/10.1073/pnas.0711183105.CrossRefPubMedPubMedCentral

25.

Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 2005;3(4):320–32. https://doi.org/10.1038/nrmicro1095.CrossRefPubMed

26.

Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, et al. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA. 2013;110(8):3047–52. https://doi.org/10.1073/pnas.1211248110.CrossRefPubMedPubMedCentral

27.

Cover TL, Krishna US, Israel DA, Peek RM Jr. Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Can Res. 2003;63(5):951–7.

28.

Chen P, Guo H, Wu X, Li J, Duan X, Ba Q, et al. Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-κB signaling pathway in gastric cancer development and progression. Carcinogenesis. 2019. https://doi.org/10.1093/carcin/bgz143.CrossRefPubMedPubMedCentral

29.

Hisatsune J, Yamasaki E, Nakayama M, Shirasaka D, Kurazono H, Katagata Y, et al. Helicobacter pylori VacA enhances prostaglandin E2 production through induction of cyclooxygenase 2 expression via a p38 mitogen-activated protein kinase/activating transcription factor 2 cascade in AZ-521 cells. Infect Immun. 2007;75(9):4472–81. https://doi.org/10.1128/iai.00500-07.CrossRefPubMedPubMedCentral

30.

Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS. 2003;111(10):915–25. https://doi.org/10.1034/j.1600-0463.2003.1111001.x.CrossRefPubMed

31.

Echizen K, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci. 2016;107(4):391–7. https://doi.org/10.1111/cas.12901.CrossRefPubMedPubMedCentral

32.

Wessler S, Krisch LM, Elmer DP, Aberger F. From inflammation to gastric cancer—the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic inflammatory and neoplastic diseases. Cell Commun Signal. 2017;15(1):15. https://doi.org/10.1186/s12964-017-0171-4.CrossRefPubMedPubMedCentral

33.

Lin L, Wei H, Yi J, Xie B, Chen J, Zhou C, et al. Chronic CagA-positive Helicobacter pylori infection with MNNG stimulation synergistically induces mesenchymal and cancer stem cell-like properties in gastric mucosal epithelial cells. J Cell Biochem. 2019;120(10):17635–49. https://doi.org/10.1002/jcb.29031.CrossRefPubMed

34.

Udhayakumar G, Jayanthi V, Devaraj N, Devaraj H. Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog. 2007;46(9):807–17. https://doi.org/10.1002/mc.20311.CrossRefPubMed

35.

Sokolova O, Naumann M. NF-κB signaling in gastric cancer. Toxins. 2017. https://doi.org/10.3390/toxins9040119.CrossRefPubMedPubMedCentral

36.

Khanna P, Chua PJ, Bay BH, Baeg GH. The JAK/STAT signaling cascade in gastric carcinoma (Review). Int J Oncol. 2015;47(5):1617–26. https://doi.org/10.3892/ijo.2015.3160.CrossRefPubMed

37.

Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96. https://doi.org/10.1016/bs.acr.2015.04.014.CrossRefPubMed

38.

Garcia HG, Berrocal A, Kim YJ, Martini G, Zhao J. Lighting up the central dogma for predictive developmental biology. Curr Top Dev Biol. 2020;137:1–35. https://doi.org/10.1016/bs.ctdb.2019.10.010.CrossRefPubMed

39.

Li X, Pasche B, Zhang W, Chen K. Association of MUC16 mutation with tumor mutation load and outcomes in patients with gastric cancer. JAMA Oncol. 2018;4(12):1691–8. https://doi.org/10.1001/jamaoncol.2018.2805.CrossRefPubMedPubMedCentral

40.

Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. Epigenomics. 2015;7(3):475–86. https://doi.org/10.2217/epi.15.4.CrossRefPubMed

41.

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–84. https://doi.org/10.1007/s10120-014-0402-y.CrossRefPubMed

42.

Kim HJ, Kim N, Kim HW, Park JH, Shin CM, Lee DH. Promising aberrant DNA methylation marker to predict gastric cancer development in individuals with family history and long-term effects of H. pylori eradication on DNA methylation. Gastric Cancer. 2021;24(2):302–13. https://doi.org/10.1007/s10120-020-01117-w.CrossRefPubMed

43.

Tahara S, Tahara T, Horiguchi N, Kato T, Shinkai Y, Yamashita H, et al. DNA methylation accumulation in gastric mucosa adjacent to cancer after Helicobacter pylori eradication. Int J Cancer. 2019;144(1):80–8. https://doi.org/10.1002/ijc.31667.CrossRefPubMed

44.

Tahara S, Tahara T, Tuskamoto T, Horiguchi N, Kawamura T, Okubo M, et al. Morphologic characterization of residual DNA methylation in the gastric mucosa after Helicobacter pylori eradication. Cancer Med. 2017;6(7):1730–7. https://doi.org/10.1002/cam4.1082.CrossRefPubMedPubMedCentral

45.

Yang J, Song H, Cao K, Song J, Zhou J. Comprehensive analysis of Helicobacter pylori infection-associated diseases based on miRNA-mRNA interaction network. Brief Bioinform. 2019;20(4):1492–501. https://doi.org/10.1093/bib/bby018.CrossRefPubMed

46.

Rossi AF, Cadamuro AC, Biselli-Périco JM, Leite KR, Severino FE, Reis PP, et al. Interaction between inflammatory mediators and miRNAs in Helicobacter pylori infection. Cell Microbiol. 2016;18(10):1444–58. https://doi.org/10.1111/cmi.12587.CrossRefPubMedPubMedCentral

47.

Li S, Liang X, Ma L, Shen L, Li T, Zheng L, et al. MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis. Oncogene. 2018;37(7):884–96. https://doi.org/10.1038/onc.2017.381.CrossRefPubMed

48.

Zhang J, Wei J, Wang Z, Feng Y, Wei Z, Hou X, et al. Transcriptome hallmarks in Helicobacter pylori infection influence gastric cancer and MALT lymphoma. Epigenomics. 2020;12(8):661–71. https://doi.org/10.2217/epi-2019-0152.CrossRefPubMed

49.

Perri F, Cotugno R, Piepoli A, Merla A, Quitadamo M, Gentile A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol. 2007;102(7):1361–71. https://doi.org/10.1111/j.1572-0241.2007.01284.x.CrossRefPubMed

50.

Hagen SJ, Ang LH, Zheng Y, Karahan SN, Wu J, Wang YE, et al. Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach. Gastroenterology. 2018;155(6):1852–67. https://doi.org/10.1053/j.gastro.2018.08.041.CrossRefPubMed

51.

Rudnicka K, Backert S, Chmiela M. Genetic polymorphisms in inflammatory and other regulators in gastric cancer: risks and clinical consequences. Curr Top Microbiol Immunol. 2019;421:53–76. https://doi.org/10.1007/978-3-030-15138-6_3.CrossRefPubMed

52.

Jin G, Lv J, Yang M, Wang M, Zhu M, Wang T, et al. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study. Lancet Oncol. 2020;21(10):1378–86. https://doi.org/10.1016/s1470-2045(20)30460-5.CrossRefPubMed

53.

Tongtawee T, Bartpho T, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Leeanansaksiri W, et al. Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis: a prospective cross-sectional study in Thailand. Eur J Cancer Prev. 2018;27(2):118–23. https://doi.org/10.1097/cej.0000000000000347.CrossRefPubMed

54.

Luo MX, Long BB, Li F, Zhang C, Pan MT, Huang YQ, et al. Roles of Cyclooxygenase-2 gene -765G > C (rs20417) and -1195G > A (rs689466) polymorphisms in gastric cancer: a systematic review and meta-analysis. Gene. 2019;685:125–35. https://doi.org/10.1016/j.gene.2018.10.077.CrossRefPubMed

55.

Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013;4(9): e794. https://doi.org/10.1038/cddis.2013.334.CrossRefPubMedPubMedCentral

56.

Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Investig. 2004;113(3):321–33. https://doi.org/10.1172/jci20925.CrossRefPubMedPubMedCentral

57.

Käbisch R, Semper RP, Wüstner S, Gerhard M, Mejías-Luque R. Helicobacter pylori γ-glutamyltranspeptidase induces tolerogenic human dendritic cells by activation of glutamate receptors. J Immunol. 2016;196(10):4246–52. https://doi.org/10.4049/jimmunol.1501062.CrossRefPubMed

58.

Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci USA. 2011;108(22):9238–43. https://doi.org/10.1073/pnas.1106200108.CrossRefPubMedPubMedCentral

59.

Tsang YH, Lamb A, Romero-Gallo J, Huang B, Ito K, Peek RM Jr, et al. Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. Oncogene. 2010;29(41):5643–50. https://doi.org/10.1038/onc.2010.304.CrossRefPubMedPubMedCentral

60.

Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 2011;60(8):1173–80. https://doi.org/10.1007/s00262-011-1008-4.CrossRefPubMed

61.

Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015;5(5):475–87. https://doi.org/10.1158/2159-8290.cd-15-0011.CrossRefPubMedPubMedCentral

62.

Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 2010;123(Pt 19):3209–14. https://doi.org/10.1242/jcs.073643.CrossRefPubMedPubMedCentral

63.

Tummers B, Green DR. Caspase-8: regulating life and death. Immunol Rev. 2017;277(1):76–89. https://doi.org/10.1111/imr.12541.CrossRefPubMedPubMedCentral

64.

van der Woude CJ, Kleibeuker JH, Jansen PL, Moshage H. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis. 2004;9(2):123–30. https://doi.org/10.1023/b:appt.0000018794.26438.22.CrossRefPubMed

65.

Naderer T, Fulcher MC. Targeting apoptosis pathways in infections. J Leukoc Biol. 2018;103(2):275–85. https://doi.org/10.1189/jlb.4mr0717-286r.CrossRefPubMed

66.

Dang Y, Zhang Y, Xu L, Zhou X, Gu Y, Yu J, et al. PUMA-mediated epithelial cell apoptosis promotes Helicobacter pylori infection-mediated gastritis. Cell Death Dis. 2020;11(2):139. https://doi.org/10.1038/s41419-020-2339-x.CrossRefPubMedPubMedCentral

67.

Posselt G, Wiesauer M, Chichirau BE, Engler D, Krisch LM, Gadermaier G, et al. Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis. Cell Commun Signal. 2019;17(1):10. https://doi.org/10.1186/s12964-019-0323-9.CrossRefPubMedPubMedCentral

68.

Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol. 2001;96(1):16–26. https://doi.org/10.1111/j.1572-0241.2001.03447.x.CrossRefPubMed

69.

D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92. https://doi.org/10.1002/cbin.11137.CrossRefPubMed

70.

Liu CJ, Wang YK, Kuo FC, Hsu WH, Yu FJ, Hsieh S, et al. Helicobacter pylori infection-induced hepatoma-derived growth factor regulates the differentiation of human mesenchymal stem cells to myofibroblast-like cells. Cancers. 2018. https://doi.org/10.3390/cancers10120479.CrossRefPubMedPubMedCentral

71.

Badrinath N, Yoo SY. Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy. Carcinogenesis. 2018;39(12):1419–30. https://doi.org/10.1093/carcin/bgy148.CrossRefPubMed

72.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. https://doi.org/10.1080/01926230701320337.CrossRefPubMedPubMedCentral

73.

Vringer E, Tait SWG. Mitochondria and inflammation: cell death heats up. Front Cell Dev Biol. 2019;7:100. https://doi.org/10.3389/fcell.2019.00100.CrossRefPubMedPubMedCentral

74.

Berthenet K, Weber K, Ichim G. Sometimes even apoptosis fails: implications for cancer. Mol Cell Oncol. 2020;7(6):1797430. https://doi.org/10.1080/23723556.2020.1797430.CrossRefPubMedPubMedCentral

75.

Larsen BD, Sørensen CS. The caspase-activated DNase: apoptosis and beyond. FEBS J. 2017;284(8):1160–70. https://doi.org/10.1111/febs.13970.CrossRefPubMed

76.

Brokatzky D, Dörflinger B, Haimovici A, Weber A, Kirschnek S, Vier J, et al. A non-death function of the mitochondrial apoptosis apparatus in immunity. EMBO J. 2019. https://doi.org/10.15252/embj.2018100907.CrossRefPubMedPubMedCentral

77.

Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell. 2015;57(5):860–72. https://doi.org/10.1016/j.molcel.2015.01.018.CrossRefPubMedPubMedCentral

78.

Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16(8):539–48. https://doi.org/10.1038/nrc.2016.58.CrossRefPubMed

79.

Riley JS, Tait SW. Mitochondria and pathogen immunity: from killer to firestarter. EMBO J. 2019. https://doi.org/10.15252/embj.2019102325.CrossRefPubMedPubMedCentral

80.

Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013;20(1):31–42. https://doi.org/10.1038/cdd.2012.81.CrossRefPubMed

81.

Dorn GW 2nd, Kitsis RN. The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res. 2015;116(1):167–82. https://doi.org/10.1161/circresaha.116.303554.CrossRefPubMed

82.

Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15(10):634–46. https://doi.org/10.1038/nrm3877.CrossRefPubMedPubMedCentral

83.

Peña-Blanco A, García-Sáez AJ. Bax, Bak and beyond—mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416–31. https://doi.org/10.1111/febs.14186.CrossRefPubMed

84.

Jeong SY, Seol DW. The role of mitochondria in apoptosis. BMB Rep. 2008;41(1):11–22. https://doi.org/10.5483/bmbrep.2008.41.1.011.CrossRefPubMed

85.

Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166(1):63–76. https://doi.org/10.1016/j.cell.2016.05.035.CrossRefPubMedPubMedCentral

86.

Yang H, Li Y, Hu B. Potential role of mitochondria in gastric cancer detection: fission and glycolysis. Oncol Lett. 2021;21(6):439. https://doi.org/10.3892/ol.2021.12700CrossRefPubMedPubMedCentral

87.

Milani M, Byrne DP, Greaves G, Butterworth M, Cohen GM, Eyers PA, et al. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. Cell Death Dis. 2017;8(1): e2552. https://doi.org/10.1038/cddis.2016.485.CrossRefPubMedPubMedCentral

88.

Maycotte P, Marín-Hernández A, Goyri-Aguirre M, Anaya-Ruiz M, Reyes-Leyva J, Cortés-Hernández P. Mitochondrial dynamics and cancer. Tumour Biol. 2017;39(5):1010428317698391. https://doi.org/10.1177/1010428317698391.CrossRefPubMed

89.

Xie LL, Shi F, Tan Z, Li Y, Bode AM, Cao Y. Mitochondrial network structure homeostasis and cell death. Cancer Sci. 2018;109(12):3686–94. https://doi.org/10.1111/cas.13830.CrossRefPubMedPubMedCentral

90.

Karbowski M, Lee YJ, Gaume B, Jeong SY, Frank S, Nechushtan A, et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol. 2002;159(6):931–8. https://doi.org/10.1083/jcb.200209124.CrossRefPubMedPubMedCentral

91.

Gruno M, Peet N, Tein A, Salupere R, Sirotkina M, Valle J, et al. Atrophic gastritis: deficient complex I of the respiratory chain in the mitochondria of corpus mucosal cells. J Gastroenterol. 2008;43(10):780–8. https://doi.org/10.1007/s00535-008-2231-4.CrossRefPubMed

92.

Yan H, Qiu C, Sun W, Gu M, Xiao F, Zou J, et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep. 2018;39(4):1671–81. https://doi.org/10.3892/or.2018.6252.CrossRefPubMedPubMedCentral

93.

Jo MJ, Jeong S, Yun HK, Kim DY, Kim BR, Kim JL, et al. Genipin induces mitochondrial dysfunction and apoptosis via downregulation of Stat3/mcl-1 pathway in gastric cancer. BMC Cancer. 2019;19(1):739. https://doi.org/10.1186/s12885-019-5957-x.CrossRefPubMedPubMedCentral

94.

Huang S, Guo Y, Li Z, Zhang Y, Zhou T, You W, et al. A systematic review of metabolomic profiling of gastric cancer and esophageal cancer. Cancer Biol Med. 2020;17(1):181–98. https://doi.org/10.20892/j.issn.2095-3941.2019.0348.CrossRefPubMedPubMedCentral

95.

Xiao S, Zhou L. Gastric cancer: Metabolic and metabolomics perspectives (Review). Int J Oncol. 2017;51(1):5–17. https://doi.org/10.3892/ijo.2017.4000.CrossRefPubMed

96.

Machado AM, Desler C, Bøggild S, Strickertsson JA, Friis-Hansen L, Figueiredo C, et al. Helicobacter pylori infection affects mitochondrial function and DNA repair, thus, mediating genetic instability in gastric cells. Mech Ageing Dev. 2013;134(10):460–6. https://doi.org/10.1016/j.mad.2013.08.004.CrossRefPubMed

97.

Yang L, Zhang W, Wang Y, Zou T, Zhang B, Xu Y, et al. Hypoxia-induced miR-214 expression promotes tumour cell proliferation and migration by enhancing the Warburg effect in gastric carcinoma cells. Cancer Lett. 2018;414:44–56. https://doi.org/10.1016/j.canlet.2017.11.007.CrossRefPubMed

98.

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9. https://doi.org/10.1038/nrc1478.CrossRefPubMed

99.

Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 2013;230(4):350–5. https://doi.org/10.1002/path.4218.CrossRefPubMedPubMedCentral

100.

Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2010;107(5):2037–42. https://doi.org/10.1073/pnas.0914433107.CrossRefPubMedPubMedCentral

101.

Yang H, Du L, Zhang Z. Potential biomarkers in septic shock besides lactate. Exp Biol Med (Maywood). 2020;245(12):1066–72. https://doi.org/10.1177/1535370220919076.CrossRef

102.

de Bari L, Atlante A. Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming. Cell Mol Life Sci. 2018;75(15):2763–76. https://doi.org/10.1007/s00018-018-2831-y.CrossRefPubMed

103.

Kim SY. Cancer energy metabolism: shutting power off cancer factory. Biomol Ther. 2018;26(1):39–44. https://doi.org/10.4062/biomolther.2017.184.CrossRef

104.

Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358-71.e9. https://doi.org/10.1016/j.cell.2017.09.019.CrossRefPubMedPubMedCentral

105.

Kaji K, Hashiba A, Uotani C, Yamaguchi Y, Ueno T, Ohno K, et al. Grading of atrophic gastritis is useful for risk stratification in endoscopic screening for gastric cancer. Am J Gastroenterol. 2019;114(1):71–9. https://doi.org/10.1038/s41395-018-0259-5.CrossRefPubMed

106.

Zhang X, Meng X, Chen Y, Leng SX, Zhang H. The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J. 2017;23(4):201–5. https://doi.org/10.1097/ppo.0000000000000270.CrossRefPubMed

107.

Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120(4):483–95. https://doi.org/10.1016/j.cell.2005.02.001.CrossRefPubMed

108.

Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062–5. https://doi.org/10.1126/science.1219855.CrossRefPubMedPubMedCentral

109.

Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell. 2011;146(5):682–95. https://doi.org/10.1016/j.cell.2011.07.030.CrossRefPubMed

110.

Kauppila TES, Kauppila JHK, Larsson NG. Mammalian mitochondria and aging: an update. Cell Metab. 2017;25(1):57–71. https://doi.org/10.1016/j.cmet.2016.09.017.CrossRefPubMed

111.

Bose S, French S, Evans FJ, Joubert F, Balaban RS. Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem. 2003;278(40):39155–65. https://doi.org/10.1074/jbc.M306409200.CrossRefPubMed

112.

Catic A. Cellular metabolism and aging. Prog Mol Biol Transl Sci. 2018;155:85–107. https://doi.org/10.1016/bs.pmbts.2017.12.003.CrossRefPubMedPubMedCentral

113.

Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4-9. https://doi.org/10.1093/gerona/glu057.CrossRefPubMed

114.

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32. https://doi.org/10.1038/s41591-019-0675-0.CrossRefPubMedPubMedCentral

115.

Vaiserman AM, Koliada AK, Marotta F. Gut microbiota: a player in aging and a target for anti-aging intervention. Ageing Res Rev. 2017;35:36–45. https://doi.org/10.1016/j.arr.2017.01.001.CrossRefPubMed

116.

Delgado S, Cabrera-Rubio R, Mira A, Suárez A, Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol. 2013;65(3):763–72. https://doi.org/10.1007/s00248-013-0192-5.CrossRefPubMed

117.

Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1–22. https://doi.org/10.1080/19490976.2021.1909459.CrossRefPubMedPubMedCentral

118.

Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019;9(1):20100. https://doi.org/10.1038/s41598-019-56631-4.CrossRefPubMedPubMedCentral

119.

Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori infection, the gastric microbiome and gastric cancer. Adv Exp Med Biol. 2019;1149:195–210. https://doi.org/10.1007/5584_2019_366.CrossRefPubMed

120.

Li TH, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in gastric microbiota After H. Pylori eradication and in different histological stages of gastric carcinogenesis. Sci Rep. 2017;7:44935. https://doi.org/10.1038/srep44935.CrossRefPubMedPubMedCentral

121.

Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaoz U, Contreras M, Blaser MJ, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5(4):574–9. https://doi.org/10.1038/ismej.2010.149.CrossRefPubMed

122.

Zhao Y, Gao X, Guo J, Yu D, Xiao Y, Wang H, et al. Helicobacter pylori infection alters gastric and tongue coating microbial communities. Helicobacter. 2019;24(2): e12567. https://doi.org/10.1111/hel.12567.CrossRefPubMedPubMedCentral

123.

He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, et al. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter. 2019;24(4): e12590. https://doi.org/10.1111/hel.12590.CrossRefPubMed

124.

Shin CM, Kim N, Park JH, Lee DH. Changes in gastric corpus microbiota with age and after Helicobacter pylori eradication: a long-term follow-up study. Front Microbiol. 2020;11: 621879. https://doi.org/10.3389/fmicb.2020.621879.CrossRefPubMed

125.

Heimesaat MM, Fischer A, Plickert R, Wiedemann T, Loddenkemper C, Göbel UB, et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS ONE. 2014;9(6): e100362. https://doi.org/10.1371/journal.pone.0100362.CrossRefPubMedPubMedCentral

126.

Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67(6):1024–32. https://doi.org/10.1136/gutjnl-2017-314281.CrossRefPubMed

127.

Arita S, Inagaki-Ohara K. High-fat-diet-induced modulations of leptin signaling and gastric microbiota drive precancerous lesions in the stomach. Nutrition. 2019;67–68: 110556. https://doi.org/10.1016/j.nut.2019.110556.CrossRefPubMed

128.

Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020;69(9):1572–80. https://doi.org/10.1136/gutjnl-2019-319826.CrossRefPubMed

129.

Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226–36. https://doi.org/10.1136/gutjnl-2017-314205.CrossRefPubMed

130.

Yu G, Torres J, Hu N, Medrano-Guzman R, Herrera-Goepfert R, Humphrys MS, et al. Molecular characterization of the human stomach microbiota in gastric cancer patients. Front Cell Infect Microbiol. 2017;7:302. https://doi.org/10.3389/fcimb.2017.00302.CrossRefPubMedPubMedCentral

131.

Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140(1):210–20. https://doi.org/10.1053/j.gastro.2010.09.048.CrossRefPubMed

132.

Lertpiriyapong K, Whary MT, Muthupalani S, Lofgren JL, Gamazon ER, Feng Y, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut. 2014;63(1):54–63. https://doi.org/10.1136/gutjnl-2013-305178.CrossRefPubMed

133.

Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, et al. Association between gut microbiota and Helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Front Cell Infect Microbiol. 2018;8:202. https://doi.org/10.3389/fcimb.2018.00202.CrossRefPubMedPubMedCentral

134.

Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2014;355(1):106–12. https://doi.org/10.1016/j.canlet.2014.09.010.CrossRefPubMedPubMedCentral

135.

Wang L, Zhou J, Xin Y, Geng C, Tian Z, Yu X, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28(3):261–6. https://doi.org/10.1097/meg.0000000000000542.CrossRefPubMedPubMedCentral

136.

Recavarren-Arce S, León-Barúa R, Cok J, Berendson R, Gilman RH, Ramírez-Ramos A, et al. Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer. Scand J Gastroenterol Suppl. 1991;181:51–7. https://doi.org/10.3109/00365529109093208.CrossRefPubMed

137.

Castaño-Rodríguez N, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7(1):15957. https://doi.org/10.1038/s41598-017-16289-2.CrossRefPubMedPubMedCentral

138.

Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11): e1006653. https://doi.org/10.1371/journal.ppat.1006653.CrossRefPubMedPubMedCentral

Titel: Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer
verfasst von: Hang Yang
Bin Wei
Bing Hu
Publikationsdatum: 21.09.2021
Verlag: Springer International Publishing
Erschienen in: Inflammation Research / Ausgabe 10-12/2021
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-021-01501-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer

Abstract

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10-12/2021

Osteoarthritic infrapatellar fat pad aggravates cartilage degradation via activation of p38MAPK and ERK1/2 pathways

Insulin/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: impact on the aging process and age-related diseases

Gisenoside Rg1 attenuates cadmium-induced neurotoxicity in vitro and in vivo by attenuating oxidative stress and inflammation

Anti-high mobility group box 1 monoclonal antibody suppressed hyper-permeability and cytokine production in human pulmonary endothelial cells infected with influenza A virus

C/EBPβ is a key transcription factor of ox-LDL inducing THP-1 cells to release multiple pro-inflammatory cytokines

Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cells—“utilization” of ferroptosis mechanism

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin